help_outline Skip to main content
HomeNews List

News / Articles

Search News / Articles

News

New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032
Published on: 8/6/2020
HOUSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the continued enhancement of the intellectual property (IP) portfolio governing its lead investigational drug candidate, seclidemstat. The European Patent Office (EPO) recently announced that the European Patent EP2744330, exclusively licensed to Salarius from the University of Utah Research Foundation, was issued on July 15, 2020.

The European patent covers composition of matter and methods of use for seclidemstat, a potent reversible inhibitor of the LSD1 enzyme which is currently the subject of a Phase 1/2 clinical trial for Ewing sarcoma, a rare pediatric bone cancer, and a Phase 1/2 trial in advanced solid tumors (AST). Salarius intends to validate this European patent in several important EU countries.

Press Releases & Articles

Keiretsu Forum Fuels Investment In Most Valued Companies and Rewards Most Active Investors
Cindi Sutera
Published on: 11/30/2020
Three sessions, six weeks, 36 high-quality investment opportunities describes this year's Keiretsu Forum Investor Capital Expo. The virtual event attracted over 900 registered accredited investors from 50 angel groups, investors from 100+ Family Offices, corporate partners, and keynotes from leading experts. To date, featured companies have more than 2,000 indications of investment interest. By all measures, it was a very successful Expo; for three investors, it was an exceptional Expo.

To encourage constructive feedback to presenting companies, investors who submit their 'gold sheet' feedback forms for all three sessions were eligible to win a $25,000 investment in the Most Valued Company Special Purpose Vehicle. The winners were drawn at random and are:

Paul Gianneschi, member of the Atlanta Chapter, Ashley Hancock, member of the Atlanta Chapter, and Brad Kollmyer, member of 1 month of the Vancouver Chapter
Virion Therapeutics Wins Prestigious 'Most Valued Company' at Keiretsu Forum Investor Capital Expo
Cindi Sutera
Published on: 11/30/2020
Virion Therapeutics, developing novel T cell based treatments for cancers and infectious diseases using the world's first genetically encoded checkpoint inhibitor, was one of three companies named a "Most Valued Company" at the virtual Keiretsu Forum Investor Capital Expo which showcased 36 premier growth-stage companies primarily in life sciences and technology. Nearly 50 angel groups, investors from 100+ Family Offices, corporate partners, and hundreds of accredited investors attended the Expo.

Virion was hand-picked by hundreds of attending angel investors as a stand-out innovator amongst a group of highly touted, entrepreneurial companies from U.S. and Canada.
Keiretsu Forum Investor Capital Expo Delivers a Grand Showcase for 36 Growth Stage Companies Primari
Cindi Sutera
Published on: 11/30/2020
Nearly 50 angel investment groups, investors from 100+ Family Offices, corporate partners, and hundreds of accredited investors from across the globe attended the Keiretsu Forum Investor Capital Expo. Over the course of the three-day virtual event, 36 premier growth-stage companies were presented. To date, more than 2,000 indications of interest from investors have been received. Philadelphia's own, Howard Lubert, Co-Founder of Keiretsu Forum Mid-Atlantic and South-East, was the mastermind behind the virtual event and worked tenaciously with the Keiretsu Forum North American team to customize an event platform that could accommodate the needs of a global investor forum.
Keiretsu Forum Kicks off Session 1 of its first Virtual Investor Capital Expo
Ryan St. John
Published on: 11/30/2020
The biggest trends in angel investing, plus 36 premier late-stage companies primarily in technology and life sciences seeking funding, are the showcase at the virtual Investor Capital Expo that kicked-off its first session October 14. The next two live sessions take place October 28 and November 11th.

Blog

EXPECT ROUGH QUARTERS. BUT IN THE LONG TERM, VENTURE INVESTMENT COULD BENEFIT FROM STOCK MARKET CRAS
Ellen Chang
Published on: 3/19/2020
EXPECT ROUGH QUARTERS. BUT IN THE LONG TERM, VENTURE INVESTMENT COULD BENEFIT FROM STOCK MARKET CRASH
THE ONLY 10 SLIDES YOU NEED IN A PITCH
Ryan St John
Published on: 3/4/2020
THE ONLY 10 SLIDES YOU NEED IN A PITCH
GEORGIA TECH COLLABORATES WITH KEIRETSU FORUM TO ADVANCE INNOVATION AND ENTREPRENEURSHIP
Ryan St. John
Published on: 2/28/2020
Keiretsu Forum South-East has entered into a resource collaboration with the Georgia Institute of Technology. The objective of this collaboration is to further innovation, entrepreneurship and technology transfer in the South-East region. This educational relationship provides entrepreneurial-minded faculty and students of Georgia Tech with exposure to well-prepared and experienced executives in a role-model context.
PORTFOLIO COMPANY, GEL-E, INC. CHANGES ITS NAME TO MEDCURA
Published on: 1/7/2020
COLLEGE PARK, Md., Dec. 19, 2019 /PRNewswire/ — gel-e, Inc., announced today that the Company has changed its name to Medcura. The corporate name change is effective [...]
KEIRETSU SPONSOR, CHRISTOPHER EZOLD, DISCUSSES TRENDS IN ANGEL INVESTMENT
Published on: 12/21/2019
Keiretsu Forum Mid-Atlantic is well-positioned as an angel investment group; we get to see many of the best deals in our space. I’ve done a survey of angel investing trends for 2020 and have been gratified to see that these trends are reflected in the deals we review each month.
HAPTX RAISES $12M AND PARTNERS WITH ADVANCED INPUT SYSTEMS
Published on: 12/21/2019
HaptX announced a $12 million fundraising round Thursday, allowing the Seattle startup to develop its next generation of virtual reality gloves and robotics.
PORTFOLIO COMPANY, LAURENT PHARMACEUTICALS, RECEIVES A CAD 2.7M FINANCING
Published on: 12/4/2019
PORTFOLIO COMPANY, LAURENT PHARMACEUTICALS, RECEIVES A CAD 2.7M FINANCING FROM BIOMED PROPULSION FUND
FIVE SUCCESS FACTORS THAT POWER UP ENTREPRENEURIAL SUCCESS
Published on: 11/12/2019
The article was written by Dr. Merom Klein PhD + Dr. Louise Yochee Klein PsyD
HOW DOES RECENT VERTEX PHARMACEUTICALS APPROVAL AFFECT PORTFOLIO COMPANY LAURENT PHARMACEUTICALS
Published on: 11/12/2019
Authored by: Radu Pislariu, MD, Laurent Pharmaceuticals | President & CEO
UBIQD EARNS THE 2019 NEW PRODUCT INNOVATION AWARD FROM FROST & SULLIVAN
Published on: 11/12/2019
UBIQD EARNS THE 2019 NEW PRODUCT INNOVATION AWARD FROM FROST & SULLIVAN FOR ITS QUANTUM DOT-ENABLED UBIGRO™ GREENHOUSE FILM
SEASONED ANGEL INVESTOR TO ADDRESS THE BARUCH S. BLUMBERG INSTITUTE’S REGIONAL BIOTECH CONFERENCE
Published on: 11/8/2019
Howard Lubert, co-founder of Keiretsu Forum Mid-Atlantic, will address entrepreneur and industry leaders at the Baruch S. Blumberg Regional Biotech Conference as they explore how early-stage companies can get investors to 'Show Me The Money'
HIGHEST HONOR AT INVESTOR CAPITAL EXPO GOES TO OTONEXUS
Published on: 10/20/2019
The over 200 angel investors participating in the Keiretsu Forum Mid-Atlantic's Investor Capital Expo selected OctoNexus as the winner of the Stephen M. Goodman Most Valued Company Award for 2019. This honor has advantages prior winners in funding and development.
CARMELL THERAPEUTICS LEVERAGES ‘COMPANY OF THE YEAR’ AWARD TO ADVANCE IND CLINICAL TRIALS
Published on: 10/7/2019
One year after winning the Stephen M Goodman Award at the 6th Annual Keiretsu Forum Angel Capital Expo, Carmell Therapeutics’ President, and CEO, Randy Hubbell reflects on what the honor meant to the Company and how they leveraged the award to achieve significant milestones. As a reminder, Carmell Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of regenerative medicine solutions to accelerate bone and soft tissue healing. Randy’s pitch at last year’s event earned him the votes from attending accredited investors to receive this distinguished award.
PORTFOLIO COMPANY, INDIGO BIOSCIENCES, ADDS NEW BOARD MEMBER
Published on: 8/19/2019
INDIGO Biosciences announces appointment of Mark McLoughlin to the Board of Directors. Mr. McLoughlin brings four decades of healthcare industry experience to the Company's Board.
PORTFOLIO COMPANY, UBIQD, ANNOUNCES NOVEL QUANTUM DOT OPTICAL FIBER TECHNOLOGY THAT DELIVERS EXTRA
Ryan St. John
Published on: 7/26/2019
PORTFOLIO COMPANY, UBIQD, ANNOUNCES NOVEL QUANTUM DOT OPTICAL FIBER TECHNOLOGY THAT DELIVERS EXTRA LIGHT TO THE LOWER CANOPY OF PLANTS
PORTFOLIO COMPANY, PITTMOSS, $1.75 MILLION FUNDRAISING – BRIAN P SCOTT FILED JUL 25 FORM D
Ryan St. John
Published on: 7/26/2019
PORTFOLIO COMPANY, PITTMOSS, $1.75 MILLION FUNDRAISING – BRIAN P SCOTT FILED JUL 25 FORM D
PORTFOLIO COMPANY, ASTARTE MEDICAL, APPOINTS GIULIA KENNEDY TO BOARD OF DIRECTORS
Ryan St John
Published on: 7/17/2019
PORTFOLIO COMPANY, ASTARTE MEDICAL, APPOINTS GIULIA KENNEDY TO BOARD OF DIRECTORS
WENDY F. DICICCO JOINS CARMELL THERAPEUTICS’ BOARD OF DIRECTORS
Ryan St. John
Published on: 7/17/2019
Carmell Therapeutics, a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, has named Wendy F. DiCicco to the Company’s Board of Directors.
UBIQD FOUNDER AND CEO DISCUSSES LEVERAGING NANOTECHNOLGY AT SCIENCEFEST
Ryan St. John
Published on: 7/12/2019
Join the Bradbury Science Museum and the Los Alamos Creative District for a special ScienceFest edition of Science On Tap.
PORTFOLIO COMPANY, NEW VIEW SURGICAL, CLOSES SERIES A ROUND
Ryan St. John
Published on: 7/12/2019
New View Surgical, Inc., an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery, announced that it closed its Series A Financing Round at $2.5 million. The financing was over-subscribed due to investor demand. New View Surgical will deploy the financing to complete the development of its VisionPort™ System, expand the company’s intellectual property portfolio and submit a 510(k) U.S. Food and Drug Administration (FDA) filing.
EXPRESSCELLS ANNOUNCES FIRST CLOSE OF SERIES A FINANCING
Ryan St. John
Published on: 7/1/2019
ExpressCells, Inc. (ExpressCells), a private genetic engineering company that creates advanced cell lines for drug discovery, today announced that it has completed the first close of its Series A financing round. The Rowan Innovation Venture Fund and Keiretsu Forum Mid-Atlantic are jointly leading this round.
HOW ASTARTE MEDICAL IS IMPROVING PREMATURE INFANT OUTCOMES
Ryan St. John
Published on: 6/17/2019
More than 380,000 babies are born prematurely in the United States every year. And the first 1,000 days of life are a critical period for a baby’s growth and brain development, especially for preterm infants. Plus maintaining a healthy gut is critical during this period. And the rapid changes in the microbiome during this period makes it challenging for NICU teams to treat infants with a highly personalized level of care.
ETRA FOUND A WAY TO CLOSE THE FUNDING GAP FOR SOUTHEAST STARTUPS
Ryan St. John
Published on: 6/10/2019
Like nature, the world of entrepreneurship, venture capital and investment abhors a vacuum.
HAPTX TO SHOWCASE AT AMAZON RE:MARS TECH SHOWCASE
Ryan St. John
Published on: 6/4/2019
Touch-transmitting Telerobotic Hand to be show cased at Amazon re:MARS
EVOLVING CASE LAW NECESSITATES NEW DUE DILIGENCE CONSIDERATIONS WHEN EVALUATING LIFE SCIENCE STARTUP
Ryan St. John
Published on: 5/20/2019
Laura R. Gordon, Ph.D. and Ronald C. Kern, Jr., Ph.D. are associates in the Philadelphia office of BakerHostetler. Their practices focus on patent prosecution and client counseling in the life science, biotechnology and pharmaceutical arenas.
PORTFOLIO COMPANY, ASTARTE MEDICAL, ANNOUNCES $5 MILLION RAISE LED BY KEIRETSU FORUM MID-ATLANTIC
Ryan St. John
Published on: 5/13/2019
Astarte Medical, a Yardley, Pa.-based software company in the precision medicine space, announced Tuesday it raised a $5 million Series A round led by Keiretsu Forum MidAtlantic.
MEMBERS INVITED TO JOIN INTELLECTUAL CAPITAL AT LOCAL EVENT
Ryan St. John
Published on: 5/2/2019
Organizers of ASPIRE 2019 invite Keiretsu Forum Mid-Atlantic members to attend this event in Philadelphia on June 12, 2019, which will collect the region’s leading investors, deal-makers, and entrepreneurs.
MID-ATLANTIC CAPITAL INVESTMENT SEES 30% GROWTH WITH KEIRETSU FORUM LEADING EARLY-STAGE CATEGORY
Ryan St. John
Published on: 4/26/2019
According to a report released this week by PitchBook-NVCA Venture Monitor, the first quarter of 2019 shows signs that this year is shaping up to be another very active year for investing, and Keiretsu Forum is leading early-stage funding.
PORTFOLIO COMPANY, UBIQD. WINNERS OF THE 2019 SXSW PITCH COMPETITION, HYPER-CONNECTED COMMUNITIES CA
Ryan St. John
Published on: 3/29/2019
UBIQD WINS 2019 SXSW PITCH COMPETITION, HYPER-CONNECTED COMMUNITIES CATEGORY
KEIRETSU FORUM, SPONSOR, EZOLD LAW FIRM, ADVISES LIFE SCIENCE ENTREPRENEURS ON FUNDING
Ryan St. John
Published on: 3/6/2019
Life sciences/biotech companies are a significant economic driver in the greater Philadelphia area, with an estimated 1,200 businesses employing nearly 50,000 people in 2017, according to the Greater Philadelphia Life Sciences Report, 2017. In my experience, there is significant growth within the early stage life sciences sector; most will need to seek capital to grow to an inflection point. Much financing is through angel investors; what used to be a purely venture capital space has opened up to professional angels, primarily through investment groups such as The Keiretsu Forum, the Mid-Atlantic Bio Angels and others.
SALARIUS PHARMACEUTICAL ACHIEVES SUCCESSFUL EXIT
SA
Published on: 2/21/2019
Keiretsu Forum Mid-Atlantic portfolio company, Salarius Pharmaceuticals, negotiated a successful exit in January. Salarius and publicly traded Flex Pharma, Inc (NASDAQ: FLKS) announced that the companies entered into a definitive merger agreement under which Flex Pharma is expected to be renamed Salarius Pharmaceuticals, Inc. and be under the leadership of Salarius’ current management team, led by Chief Executive Officer, David Arthur.
KEIRETSU FORUM RANKED #1 ANGEL GROUP BY PITCHBOOK FOR THIRD YEAR IN A ROW
Ryan St. John
Published on: 2/6/2019
Keiretsu Forum is listed as the number #1 “most active global investor by VC deal count” in the PitchBook Global League Tables for the third year in a row.